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A B S T R A C TObjectives: A rising trend of incidence and prevalence of ulcerative
colitis (UC) had been noticed in Asian countries. We conducted this
study to investigate the epidemiology and medical burden of UC in
Taiwan. Methods: In this 10-year retrospective database study, we
identified cases of patients with UC during 1998 to 2008 from the
Taiwan National Health Insurance Research Database. Patients who
had a catastrophic illness certificate were included in epidemiology
and medical burden calculation. Results: There were 1522 cases
identified in our study period. The incidence increased twofold from
0.37 per 100,000 in 1998 to 0.78 per 100,000 in 2008. The incidence and
prevalence had an increasing trend in our population. The cases onset age
was 45.0 years on average. In our survey, most of the top 20 coexisting
diseases were gastrointestinally relevant diseases, anemia (9.99%), and
hypertension (7.69%). There were more than 70% patients usingsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.02.006
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ondence to: Yaw-Bin Huang, No. 100, Shihcyuan 1smesalamine, and the medical expenditure on mesalamine occupied the
highest position in patients with UC. The average medical expenditure of
patients with UC had a decreasing trend after 2001. Conclusions: This
study had the largest sample and the longest study period for the
epidemiology and medical burden estimation of UC in Taiwan. The
incidence rates and medicine use of patients with UC had a definite
rising trend across the years in Taiwan. Patients with anemia or choric
diseaseswere observed in our population. More surveillance of UC-related
diseases and health care costs need to be conducted in the future.
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ulcerative colitis.
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Ulcerative colitis (UC) is a rare idiopathic inflammatory disease of
the colon and the rectum that makes the estimation of incidence
and prevalence rates difficult in Asians. A number of studies have
shown that the prevalence and incidence of UC are increasing in
Asians, especially in East Asian countries, including Hong Kong,
Korea, and Japan [1–5], although the exact etiology and mecha-
nisms for this trend are not clear [6–8]. Multiple factors may be
involved, including lifestyle [9,10], environment factors [11],
genetics [12–17], gender, and the immunological system [18,19].
Upon reviewing previous research, we found that only one study
had reported the prevalence rates of UC by using data from a
tertiary referral center in Taiwan [20]. As a result, the current
report on UC epidemiologic outcome in Taiwan was limited
[21–24].
Furthermore, a number of studies noted that the clinical
features and natural history of Asian patients with UC may be
different from those of Western patients, including extent ofdisease, relapse rate, incidence of colorectal cancer (CRC), and
mortality [7,25,26]. The symptoms and signs of UC include distal
colitis, extensive colitis, diarrhea mixed with blood and mucus,
constipation, weight loss, crampy pain, abdominal pain, low-
grade fever, and anemia [27,28]. Moreover, a recent study showed
that anemia is very common in inflammatory bowel disease and
the prevalence in patients with inflammatory bowel disease
ranged from 9% to 74% [29]. UC can also be associated with local
and extraintestinal complications. There are some severe local
complications of UC, including fulminant colitis, intestinal per-
foration and stricture, massive hemorrhage, and the develop-
ment of CRC [2,30]. A numbers of studies have also indicated that
UC may be associated with a number of extraintestinal compli-
cation, including iritis, arthritis, panniculitis, and deep venous
thrombosis [31–33]. Therefore, appropriate diagnosis and treat-
ment are important in UC. In most cases of UC, the treatment
goals are prolonging remission, decreasing prognosis of disease
severity, and increasing quality of life as previous reports have
shown that patients with UC are associated with decreasingSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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on the economic burden of patients with UC is currently limited.
A previous report in the United States described the mean annual
costs of $5066 for UC in 10,364 patients from year 2003 to 2004,
with 73% of the costs being attributable to hospitalization and
outpatient care and 27% to pharmaceutical claims [37]. Despite
the study demonstrating the substantial economic burden of UC,
the time trend of medical costs in managing patients with UC
could not be observed in this study.
The aims of this study were 1) to investigative the incidence,
prevalence, and coexisting diseases of UC in Taiwan, using a 10-
year nationwide population-based database, and 2) to describe
the distribution of drug utilization and medical expenditures of
treatment of UC in Taiwan between inpatients and outpatients.Methods
This is a population-based retrospective study for which data on
patients with UC were extracted from the list of catastrophic
illness (CI) certificates published during 1997 to 2008 by the
Department of Health, Executive Yuan of Taiwan. UC cases were
identified by using the International Classification of Diseases, Ninth
Revision code 556. A UC diagnosis on a CI certificate needs to be
strictly evaluated by at least two gastroenterologists according to
the laboratory data and images from applied hospital (sigmoido-
scopy and biopsies of the mucosa is the standard criterion used
by the Taiwan government), and all documents are rechecked by
a third physician in the Department of Health before a CI
certificate is issued. Patients with CI certificates are eligible for
exemption from insurance premiums and co-payments in
National Health Insurance. The approval of the CI certificate
needs strict evaluation by the Department of Health, and it may
lead to underestimation of the actual number of cases. Although
the actual number of cases may be underestimated, UC diagnosis
and coding are accurate. We extracted the medical records of UC
cases from the National Health Insurance Research Database
(NHIRD). The National Health Research Institute provided the
database, and the database includes information on outpatient,
ambulatory, hospital inpatient care, dental services, and pre-
scription drugs. Because this study was based in part on data
from the NHIRD, which in this study consisted of de-identified
secondary data released to the public for research purposes, this
study was exempt from full review by the ethical committee, and
informed consent did not need to be obtained from study
subjects. In this study, subjects with UC CI certificates were
included for the calculation of incidence and prevalence rates
(1998–2008).
The following data were included for analysis: gender, onset
of diagnosis age, and top 20 coexisting diseases after UC diag-
nosis. The new case numbers in each year were recorded to
calculate the annual incidence rate from 1998 to 2008. The
incidence rate for the CI certificates was calculated to track their
first UC medical claim date. The prevalence rate for the CI
certificates was also calculated to track their first yearly UC
medical claim date.
For assessing time trend of medical costs in the treatment of
patients with UC, we focused on drug utilization and medical
expenditures in each year, and categorized medication into the
following categories: 5-aminosalicylic acid derivate (including
mesalamine and sulfasalazine, which were common use in
Taiwan), corticosteroids, and immunosuppressant agents (aza-
thioprine, cyclosporine, 6-mercatopurine, and Tacrolimus). Oth-
erwise, each medical claim was classified as inpatient or
outpatient. To compare the average medical expenditure in the
treatment of patients with UC with that of the general Taiwan
population in each year, we quote the average medicalexpenditure per UC patient fold to average expenditure on
medicine per capita from National Health Expenditure, published
by the Department of Health, Executive Yuan of Taiwan (http://
www.doh.gov.tw/EN2006/DM/DM2.aspx?now_fod_list_no=12117
&class_no=390&level_no=2).Statistics
The crude incidence rate was calculated by using the total
number of residents in each year from 1998 to 2008 as the
denominator and the total number of new cases of patients with
UC in each year as the numerator. The crude prevalence rate was
calculated by using the total number of residents in each year as
the denominator and the total number of cases of patients with
UC in each year as the numerator. The incidence and prevalence
rates were expressed as the number of cases per 100,000. We
adjusted incidence and prevalence rates by age by using the
standard population of the year 2000. Medical expenditure was
calculated in each category (mesalamine, sulfasalazine, cortico-
steroids, and immunosuppressant agents) by outpatient, inpa-
tient, and total medical claims each year. Average medical
expenditure per patient with UC in each year from 1998 to 2008
was calculated by using all medical services expenditure in that
year as the denominator and the total number of medical users in
that year as the numerator. We also compared the average
medical expenditure per UC patient fold to the average medical
expenditure per capita in Taiwan from 1998 to 2008. All statistical
analyses were carried out by using SAS 9.2.Results
Among 10-year follow-up in Taiwan population, 1522 cases (945
males and 577 females) were identified. During 1998 to 2008,
there were 1518 new cases. The 10-year average crude incidence
rate was 0.66 patients with UC per 100,000 (Table 1). The crude
incidence rate in 1998 was 0.37 per 100,000 and in 2008 was 0.78
per 100,000 in our population. The age-adjusted incidence rate in
1998 and 2008 was 0.38 and 0.72 per 100,000, respectively. Despite
the fact that the incidence rate over the past decade had risen
twofold from 1998 to 2008 in Taiwan, there was quite a lot of
variation in the rate from year to year. The crude incidence rate
increased by 84% from 1998 to 2003 and slightly increased by 10%
from 2003 to 2008. The peak incidence rate during 1998 to 2008 in
this population was 0.81 per 100,000 in 2007. From 1998 to 2008,
the male to female ratio of new cases ranged from 1.25 to 2.18.
The crude prevalence rate in 1998 and 2008 was 0.39 per 100,000
and 4.62 per 100,000, respectively. Over the 10-year period, the UC
incidence and prevalence rates had an increasing trend in our
populations.
The onset age (mean  SD) of new UC cases was 45.08  15.04
years on average during 1998 to 2008. The onset age was stable
with each year, with the lowest ranging from 42.76  15.09 years
in 2005 to the highest ranging from 46.97  15.77 years in 2000.
The onset age for females (46.21  13.1 years) was slightly more
than that for males (44.42  15.08 years) on average during 1998
to 2008 (Table 2). On the onset age distribution of UC, the disease
onset of UC was found to range from children to elderly and
predominant at the 30 to 49 years age group for both males and
females. The peak age-specific incidence and prevalence of UC
was in the 50 to 59 years age group (Table 3). The age of patients
with UC showed a stable trend during 1998 to 2008 (Table 4).
However, the age gap between the most young and the most old
had sustained, rising over the past decade for both males and
females.
Table 2 – Onset age of ulcerative colitis in Taiwan, 1998–2008.
Year New cases Males Females
N Mean  SD Min Max N Mean  SD Min Max N Mean  SD Min Max
1998 81 46.20  15.19 16.25 76.42 45 46.21  15.73 20.70 76.42 36 46.17  14.70 16.25 72.88
1999 114 46.21  14.54 11.95 80.01 77 45.88  15.01 11.95 78.18 37 46.90  13.69 20.83 80.01
2000 93 44.31  14.99 4.25 83.59 62 44.43  13.65 20.27 83.59 31 44.08  17.61 4.25 74.72
2001 105 44.99  14.24 15.29 76.41 72 43.83  15.02 15.89 76.41 33 47.52  12.20 15.29 74.73
2002 148 44.75  14.22 3.03 79.45 91 43.03  14.56 3.03 77.37 57 47.48  13.33 26.51 79.45
2003 153 46.97  15.77 15.64 80.72 95 45.85  16.05 16.47 80.72 58 48.80  15.26 15.64 76.97
2004 131 46.76  14.67 13.80 86.41 81 46.77  13.92 13.80 86.41 50 46.75  15.96 17.19 80.96
2005 147 42.76  15.09 11.93 86.03 94 42.31  14.31 15.90 86.03 53 43.57  16.49 11.93 73.29
2006 182 43.67  16.52 9.62 90.26 107 43.42  17.10 9.62 90.26 75 44.03  15.75 11.00 82.84
2007 186 46.03  15.57 2.94 82.37 114 44.35  15.46 15.18 82.37 72 48.70  15.48 2.94 79.20
2008 182 43.24  14.66 1.71 86.64 107 42.50  15.10 1.71 86.64 75 44.30  14.05 12.23 81.82
ICD, International Classification of Diseases.
 Series accidents and disease of ICD:556.
Table 1 – Incidence and prevalence of ulcerative colitis in Taiwan, 1998–2008.
Year New cases Incidence Total cases Prevalence
T M F T1 T2 M F M/F T M F T1 T2 M F M/F
1998 81 45 36 0.37 0.38 0.40 0.34 1.25 85 49 36 0.39 0.39 0.44 0.34 1.36
1999 114 77 37 0.52 0.53 0.68 0.35 2.03 181 110 71 0.82 0.83 0.97 0.67 1.53
2000 93 62 31 0.43 0.43 0.56 0.28 2.06 245 156 89 1.11 1.11 1.39 0.82 1.78
2001 105 72 33 0.47 0.46 0.63 0.30 2.18 320 207 113 1.44 1.42 1.83 1.03 1.85
2002 148 91 57 0.66 0.64 0.79 0.52 1.60 434 274 160 1.94 1.89 2.40 1.45 1.73
2003 153 95 58 0.68 0.66 0.83 0.52 1.66 525 328 197 2.33 2.24 2.86 1.78 1.67
2004 131 81 50 0.58 0.54 0.70 0.46 1.59 574 361 213 2.54 2.4 3.14 1.92 1.69
2005 147 94 53 0.65 0.62 0.81 0.47 1.77 654 414 240 2.87 2.67 3.58 2.14 1.73
2006 182 107 75 0.79 0.75 0.91 0.66 1.41 807 499 308 3.52 3.26 4.30 2.73 1.62
2007 186 114 72 0.81 0.74 0.99 0.63 1.60 955 594 361 4.16 3.71 5.12 3.18 1.65
2008 182 107 75 0.78 0.72 0.91 0.65 1.43 1087 673 414 4.62 4.11 5.67 3.55 1.63
F, female; ICD, International Classification of Diseases; M, male; M/F, male-to-female ratio; T, total.
T1, crude rate.
T2, age-standardized rate, 2000 population in Taiwan as standard population.
 Series accidents and disease of ICD: 556.
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Table 3 – Age distribution of ulcerative colitis in Taiwan, 1998–2008.
Age group (y) New cases Incidence Total cases Prevalence
T M F T M F M/F T M F T M F M/F
o20 51 32 19 0.08 0.09 0.06 1.68 137 71 66 0.2 0.2 0.20 1.08
20–29 203 148 55 0.49 0.70 0.27 2.69 567 411 156 1.36 1.93 0.76 2.63
30–39 360 222 138 0.87 1.06 0.68 1.61 1229 812 417 2.98 3.89 2.05 1.95
40–49 359 223 136 0.90 1.11 0.69 1.64 1526 973 553 3.85 4.86 2.81 1.76
50–59 295 175 120 1.13 1.34 0.91 1.46 1233 735 498 4.71 5.63 3.79 1.48
60–69 155 86 69 0.95 1.08 0.83 1.25 689 388 301 4.23 4.88 3.61 1.29
70þ 99 59 40 0.64 0.74 0.54 1.48 486 275 211 3.15 3.44 2.83 1.30
F, female; ICD, International Classification of Diseases; M, male; M/F, male-to-female ratio; T, total.
 Series accidents and disease of ICD: 556.
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included irritable bowel syndrome (26.87%), other unspecified
noninfectious gastroenteritis and colitis (22.74%), and hemor-
rhoids (21.88%). More than 70% of the patients had a concomitant
diagnosis of gastrointestinally relevant diseases about symptoms
and signs of UC (Table 5). Among 1522 patients with UC,
comorbidities about the ventilatory diseases included acute
nasopharyngitis (6.64%) and upper respiratory tract infections
(14.91%). The chronic diseases noted were hepatitis (7.36%),
diabetes (6.64%), and hypertension (7.69%). Anemia complication
was seen in 9.9% (n ¼ 152) of the cases.
Based on medical expenditure data, four medical categories
treated in outpatients with UC increased in number of patients
and medical expenditure with time from 1998 to 2008 (Table 6). By
comparing with outpatients, the proportion of each medical
category usage and medical expenditure for inpatients remained
steady and varied from year to year. Among the four medical
categories, mesalamine accounted for the largest proportion of
medical users. The average proportion of mesalamine users to
total cases was 74%, and the proportion in each year remained
stable from 1998 to 2008. In our survey, the average proportions of
sulfasalazine and corticosteroid users to total cases were 20% and
31%, respectively. Despite the fact that the number of immuno-
suppressant agent users within the four medical categories in
outpatients and inpatients accounted for the lowest in each year,
the total immunosuppressant agent expenditure still remained
second highest within the four medical categories after 2004. TheTable 4 – Prevalence age of ulcerative colitis in Taiwan,
Year Total cases M
N Mean  SD Min Max N Mean 
1998 85 46.33  15.08 16.25 76.42 49 46.45  1
1999 181 46.07  14.56 11.95 80.01 110 45.72  1
2000 245 46.25  14.50 4.25 83.59 156 45.52  1
2001 320 46.34  14.56 4.65 84.12 207 45.55  1
2002 434 46.46  14.48 3.03 84.79 274 45.20  1
2003 525 47.49  14.89 3.81 83.46 328 46.32  1
2004 574 47.95  14.41 4.74 86.41 361 46.98  1
2005 654 47.76  14.65 5.68 86.62 414 46.44  1
2006 807 47.37  15.01 6.74 90.26 499 46.82  1
2007 955 47.56  14.99 2.94 91.23 594 46.89  1
2008 1087 47.37  15.04 1.71 91.52 673 46.69  1
ICD, International Classification of Diseases.
 Series accidents and disease of ICD: 556.highest proportion of immunosuppressant agent users to total
cases was in 2008 at 7% and the lowest in 1998 at 0%, with the
number of drug users increasing twofold from 2006 to 2008.
The average medical expenditure per patient with UC was
13,964 NTD, representing 1.7-fold to the average medical expen-
diture per each Taiwan population member in 2008 (Table 7).
Furthermore, despite an increase in the total cases and medical
users with time in our survey, the average medical expenditure of
patients with UC remained decreasing and the proportion of
average medical expenditure in patients with UC to that in the
general population also decreased with time from 2001 to 2008.Discussion
UC has been widely discussed in Western countries and been
considered as a rare disease among Asian countries [2,6,8,38]. In
the past two decades, a number of articles have shown a rising
trend in the prevalence and incidence of UC in Asian countries,
especially in East Asian countries (Table 8) [1,3–5,39–46]. In our
study, the incidence rate (0.38–0.72 per 100,000) in Taiwan is
similar to that in Hong Kong (0.40 per 100,000) [1], but lower than
that in India (6.02 per 100,000) [45] and Lebanon (4.1 per 100,000)
[42]. Furthermore, the trend of age-adjusted incidence rate
observed across the entire time frame appeared as a rising trend
in the Taiwan population. Our present study is consistent with
South Korean studies, which found a sustained rising trend of UC1998–2008.
ales Females
SD Min Max N Mean  SD Min Max
5.50 20.70 76.42 36 46.17  14.70 16.25 72.88
4.98 11.95 78.18 71 46.61  13.96 16.76 80.01
4.19 19.75 83.59 89 47.53  15.02 4.25 76.65
4.42 15.89 84.12 113 47.78  14.77 4.65 77.60
4.50 3.03 84.79 160 48.62  14.23 5.70 79.45
4.99 3.81 83.46 197 49.44  14.56 6.68 79.74
3.97 4.74 86.41 213 49.60  15.02 7.72 80.96
4.04 5.68 86.03 240 50.03  15.41 9.18 86.62
4.85 6.74 90.26 308 48.25  15.26 9.63 82.84
4.83 8.18 91.23 361 48.66  15.22 2.94 83.52
4.89 1.71 91.52 414 48.48  15.23 3.68 82.17
Table 5 – The top 20 coexisting diseases of patients with ulcerative colitis at onset of ulcerative colitis in
Taiwan, 1998–2008 (N ¼ 1522).
ICD-9 Frequency % Disease name
564.1 409 26.87 Irritable bowel syndrome
558.9 333 21.88 Other and unspecified noninfectious gastroenteritis and colitis
465.9 227 14.91 Acute upper respiratory infections of unspecified site
536.9 217 14.26 Unspecified functional disorder of stomach
455.6 203 13.34 Unspecified hemorrhoids without mention of complication
789 184 12.09 Other symptoms involving abdomen and pelvis
533.9 175 11.50
Peptic ulcer, site unspecified, unspecified as acute or chronic, without
mention of hemorrhage or perforation
564.9 172 11.30 Unspecified functional disorder of intestine
285.9 152 9.99 Anemia, unspecified
578.9 147 9.66 Hemorrhage of gastrointestinal tract, unspecified
455 143 9.40 Hemorrhoids
564 129 8.48 Functional digestive disorders, not elsewhere classified
555.1 125 8.21 Regional enteritis, large intestine
536.8 124 8.15 Dyspepsia and other specified disorders of function of stomach
455.8 119 7.82 Unspecified hemorrhoids with other complication
401.9 117 7.69 Essential hypertension, unspecified
571.4 112 7.36 Chronic hepatitis
300 106 6.96 Neurotic disorders
250 101 6.64 Diabetes mellitus
460 101 6.64 Acute nasopharyngitis (common cold)
ICD-9, International Classification of Diseases, Ninth Revision.
 Series accidents and disease of ICD:556.
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adjusted prevalence rates (3.26 per 100,000) in 2006 are lower than
those in other East Asian countries, such as Hong Kong (6.99 per
100,000) [1], Japan (63.6 per 100,000) [3], and South Korea (30.9 per
100,000) [5]. The reason of lower prevalence rates in our popula-
tion may come from the CI certificate needing strict evaluation by
two specialty physicians in the Department of Health, which
leads to the actual number of cases being underestimated. Also,
accurate case numbers may be underestimated owing to patients
who died before they could apply for a CI certificate and owing to
patients who did not apply for a CI certificate. However, the rising
trend of prevalence rates in our findings is also consistent with
other recent studies.
Our study findings were consistent with most studies that the
male is the predominant gender (M/F ¼ 1.25:1–2.5:1) in patients
with UC [3,18,19]. Furthermore, the onset age of new UC cases
was 45.08 years and the predominant age range was 30 to 49
years, which is similar as in other studies in Asia [3,21]. In
contrast to other studies, our data showed that the peak age-
specific incidence and prevalence rates were in the 50 to 59 years
age group.
The signs and symptoms of UC patients can be associated
with different gastrointestinal signs and symptoms, and local or
extraintestinal complications with no treatment patients. In our
findings, more than 70% of coexisting diseases in patients with
UC were signs and symptoms of UC. Local complications, such
as massive hemorrhage, intestinal perforation or stricture, and
colon cancer, would occur in a number of patients with UC
[30,47,48]. CRC is a serious complication in patients with UC, and
a number of studies showed that Asian patients have lower
incidence rates (0%–1.8%) than do Western patients (3%–5%) [47].
Despite this, we did not find CRC in the top 20 coexisting
diseases from our results; 10-year CRC prevalence still observed
a rate of 4.99% for colon cancer and 0.59% for rectum and anal
canal cancer. Moreover, a lower CRC risk was observed for Asian
patients with UC from current studies, but more studies need tobe performed for CRC surveillance in Asian patients with UC. In
our results, anemia had a high disease prevalence (9.99%) in our
population from our database. Similarly, a number of studies
indicated that anemia is a common complication in patients
with UC and the mechanism of anemia with UC diseases may be
due to gastrointestinal bleeding, poor absorption, iron deficiency,
and disease severity [29]. Some recent studies showed that
chronic diseases, including hypertension and metabolic syn-
drome, were a common condition within patients with UC
[21,49]. Our findings are consistent with other studies that
diabetes (6.64%) and hypertension (7.69%) are observed in the
top 20 coexisting diseases with UC.
No recent studies have reported the medical expenditure and
use trend of patients with UC in Asian countries. Therefore, our
study represents an important contribution to the current liter-
ature describing the medical burden of patients with UC. From
the results, we see that for four medical categories (mesalamine,
sulfasalazine, corticosteroids, and immunosuppressant agents)
used for the treatment of patients with UC, medical users and
expenditure increased across time from 1998 to 2008. Comparing
inpatient with outpatient episodes, we see that there was a lower
proportion of each medical category usage and expenditure at
the inpatient level and the proportion of inpatients using the
medicines remained steady with time. Between years 1998 and
2008, the proportion of different categories of medical users to
total cases had the same trend in mesalamine (72%–76%),
sulfasalazine (20%–27%), and corticosteroids (30%–35%), but a
rising trend in immunosuppressant agent users from 0% in
1998 to 7% in 2008. In addition, it was evident from the study
that the number of patients prescribed immunosuppressant
agents had the lowest drug expenditure and average drug
expenditure from 2001 to 2008 remained second highest. This
signified the urgency in discussing pharmacoeconomic strategies
of immunosuppressant agent treatment in patients with UC. In
our survey, the average medical expenditure of patients with UC
remained decreasing from 2001 to 2008, and the proportion of
Table 6 – Each drug’s utilization and expenditure in outpatient, inpatient, and total cases of patients with ulcerative colitis in Taiwan, 1998–2008.
Drug Year Outpatient Inpatient Total
No. of patients for
whom prescribed
Total drug
expenditure (NTD)
No. of patients for
whom prescribed
Total drug
expenditure (NTD)
No. of patients for
whom prescribed
% to
total
Average drug
expenditure (NTD)
Mesalamine 1998 55 630,849 11 38,304 61 72 10,970
1999 128 3,382,937 24 141,215 137 76 25,724
2000 171 3,743,754 26 125,202 182 74 21,258
2001 229 5,022,899 32 181,330 238 74 21,867
2002 313 5,008,396 38 125,719 323 74 15,895
2003 377 6,125,535 54 177,698 392 75 16,080
2004 406 6,409,686 49 184,954 417 73 15,814
2005 456 7,959,271 52 185,239 468 72 17,403
2006 586 8,970,021 71 179,897 597 74 15,326
2007 702 10,293,105 73 204,552 708 74 14,827
2008 818 11,777,123 89 239,629 822 76 14,619
Sulfasalazine 1998 14 32,202 6 3,931 19 22 1,902
1999 32 107,965 8 7,657 39 22 2,965
2000 46 213,375 9 9,752 49 20 4,554
2001 67 359,286 9 6,933 71 22 5,158
2002 95 501,087 13 11,646 103 24 4,978
2003 124 557,645 21 13,996 136 26 4,203
2004 146 620,250 21 12,287 153 27 4,134
2005 150 685,829 23 11,408 158 24 4,413
2006 162 688,628 22 13,345 165 20 4,254
2007 173 609,232 19 9,423 177 19 3,495
2008 188 579,527 19 5,945 193 18 3,034
Corticosteroids 1998 10 2214 11 603 18 21 157
1999 49 12,650 20 1,227 60 33 231
2000 69 18,343 31 1,677 86 35 233
2001 90 36,935 30 7,886 100 31 448
2002 122 54,015 37 8,330 133 31 469
2003 141 45,292 50 3,602 164 31 298
2004 165 46,767 50 4,150 174 30 293
2005 192 53,724 51 4,851 204 31 287
2006 245 56,791 64 3,266 255 32 236
2007 286 79,152 66 6,028 293 31 291
2008 344 94,158 84 7,138 353 32 287
Immunosuppressant
agents
1998 0 0 0 0 0 0 0
1999 1 902 0 0 1 1 902
2000 2 1,578 1 773 3 1 784
2001 4 21,556 3 2,963 5 2 4,904
2002 7 29,086 3 2,175 7 2 4,466
2003 13 42,175 3 3,748 14 3 3,280
2004 15 84,591 6 6,264 19 3 4,782
2005 21 125,674 5 17,155 21 3 6,801
2006 32 166,919 5 7,352 33 4 5,281
2007 43 368,404 11 32,002 47 5 8,519
2008 69 571,451 18 18,341 72 7 8,192
V
A
L
U
E
I
N
H
E
A
L
T
H
R
E
G
I
O
N
A
L
I
S
S
U
E
S
2
(
2
0
1
3
)
1
2
7
–
1
3
4
1
3
2
Table 7 – Medical expenditure of ulcerative colitis compared with general population medical expenditure in
Taiwan, 1998–2008.
Year Total
cases
No. of
patients
for
medication
No. of
patients
for
medical
service
All medical
service
expenditures (NTD)
Average
medical
expenditure
per patient
(NTD)
Average medical
expenditure per
each Taiwan
population
member (NTD)
Average
medical
expenditure
fold to general
population
1998 85 76 303 712,283 9,372 5,003 1.9
1999 181 160 1,604 3,654,553 22,841 5,537 4.1
2000 245 208 2,142 4,117,975 19,798 5,857 3.4
2001 320 280 3,112 5,640,673 20,145 5,875 3.4
2002 434 383 3,902 5,742,119 14,992 6,117 2.5
2003 525 469 4,427 6,970,943 14,863 6,592 2.3
2004 574 513 5,049 7,405,209 14,435 7,126 2.0
2005 654 575 6,286 9,094,475 15,816 7,199 2.2
2006 807 713 7,669 10,150,886 14,237 7,495 1.9
2007 955 832 9,342 11,706,148 14,070 7,970 1.8
2008 1,087 957 10,995 13,363,700 13,964 8,196 1.7
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 2 7 – 1 3 4 133average medical expenditure in patients with UC to that in the
general population also decreased with time. The reason of the
decreasing tread may be fluctuations in medical payment prices
and health care policies. There are limited data on the correlation
between medical trends of patients with UC and health care
policy, but it may be prudent to monitor patients with UC for
disease burden after UC diagnosis.
This study had the largest sample and the longest study
period for the estimation of incidence and prevalence rates of
UC in Taiwan. Although a number of studies have been con-
ducted in Asians, they still lack epidemiology information and
study in our population. We conducted the study by using the
NHIRD. This database is from one single-payer National Health
Insurance program that enrolled 98% of Taiwan’s population.
This database includes complete Taiwan population medical
records. In our study, we ascertained UC cases from CI certifi-
cates, which are evaluated by two specialty physicians, which
decreases the problem of diagnostic accuracy. There are, how-
ever, some limitations in the present study. First, UC patients
applying for CI certificates were selected on the basis of their
first claim date; therefore, a time delay may be present in this
study. Unfortunately, the database used in our study was a de-
identified secondary database. Therefore, it is difficult toTable 8 – Updated epidemiology studies of ulcerative co
Area Country Study period
East Asian Taiwan (present study) 1998–2008
Japan [4] 1991
Japan [3] 2005
Hong Kong [1] 1997–2006
Hong Kong [39] 2001
Hong Kong [40] 2006
South Korea [5] 1986–2005
South-East Asian Singapore [41] 2004
West Asian Lebanon [42] 2000–2004
Kuwait [43] 1985–1999
Israel, Kibbutz [44] 1987–1997
South Asian North India, Punjab [45] 1999–2000
Sri Lanka [46] 2007–2008determine whether underestimation occurred. Second, informa-
tion on personal habits such as smoking, lifestyle, body weight,
and disease severity was not available from the NHIRD. Some
articles have discussed the disease severity condition and
clinical characteristics of UC are different in Asian and Western
populations. In the present study, we were unable to evaluate
the severity in other countries and compare the severity of
associated signs and symptoms with data from other countries
or populations. Third, we had no imaging findings or data of
patients with UC, and these might be potential confounders.
Last, the health care policy, area of residence, individual coun-
tries, and socioeconomic status were still not included in our
outcome.
In conclusion, UC in Taiwan still presents a rare disease than
in Western countries. However, the rising trend of incidence and
prevalence rates in Asian countries has been discussed and
observed in the past decade. In Taiwanese population, UC also
had a definite rising trend in prevalence and incidence rates from
1998 to 2008. The epidemiological results were similar to those in
some East Asian countries but different from those in Western
and West Asian countries. More than 70% of the patients with UC
were using mesalamine in Taiwan, but the mesalamine expendi-
ture also kept on increasing each year. Immunosuppressantlitis in Asians.
Incidence per million per year Prevalence per million
0.78 4.62
1.95 18.1
– 63.6
0.4 6.99
1.2 –
2.1 26.5
3.08 30.87
– 6.0
4.1 106.2
2.80 41.7
5.04 167.2
6.02 44.3
0.69 5.3
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 2 7 – 1 3 4134agents had the lowest users and the second highest medical
expenditure. Decreasing medical expenditure trends in patients
with UC were observed after 2001. In the future, the UC patient
survey outcomes, clinical features, and medical treatment need
to be explored in our population to help clinical services and
treatment becoming more better and approaching perfection day
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